Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 11/20 | 0.67 |
| ▸ | CA9 | Q16790 | 9/20 | 0.67 |
| ▸ | CA12 | O43570 | 6/20 | 0.67 |
| ▸ | CA4 | P22748 | 4/20 | 0.67 |
| ▸ | CA6 | P23280 | 4/20 | 0.67 |
| ▸ | CA5A | P35218 | 4/20 | 0.67 |
| ▸ | CA7 | P43166 | 4/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607623 | 0.88 | CA2 (1.00) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL607046 | 0.86 | CA2 (1.00) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL9126817 | 0.84 | CA2 (0.96) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL10661919 | 0.84 | CA2 (0.96) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL17817182 | 0.84 | CA2 (0.96) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL28640316 | 0.84 | CA2 (0.96) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL78265 | 0.84 | CA2 (0.96) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL7898294 | 0.84 | CA2 (0.96) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL16129968 | 0.83 | CA2 (0.70) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL18122304 | 0.83 | CA2 (0.89) | CA2SMN1; SMN2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024048615-A1 | METHOD FOR PRODUCING QUINOXALINE DERIVATIVE | 協和キリン株式会社 | 2024-03-07 | — | — | WO | claimed |
| CN-113527152-A | Biphenylsulfonamide compound and method for preventing and treating crop pests by using same | 西北农林科技大学 | 2021-10-22 | — | — | CN | claimed |
| US-10201957-B2 | Dye receiving layer composition, dye receiving substrate and method of fabricating the same | CHIEN HWA COATING TECHNOLOGY , INC. (TW) | 2019-02-12 | — | — | US | claimed |
| EP-3363650-A1 | DYE RECEIVING LAYER COMPOSITION, DYE RECEIVING SUBSTRATE AND METHOD OF FABRICATING THE SAME | Chien Hwa Coating Technology, Inc. (TW) | 2018-08-22 | — | — | EP | claimed |
| CN-102802416-A | Fungicidal mixtures | BASF SE | 2012-11-28 | — | — | CN | claimed |
| CN-102595903-A | Fungicidal mixtures | BASF SE | 2012-07-18 | — | — | CN | claimed |
| CN-102458124-A | Fungicidal mixtures | BASF SE | 2012-05-16 | — | — | CN | claimed |
| EP-2097414-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2008079906-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| EP-1805442-A2 | HYDROLYSIS RESISTANT POLYAMIDE COMPOSITIONS AND ARTICLES FORMED THEREFROM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006047775-A2 | HYDROLYSIS RESISTANT POLYAMIDE COMPOSITIONS AND ARTICLES FORMED THEREFROM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-05-04 | — | — | WO | claimed |
| CN-1177832-C | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | ���ĵ�˹ҩƷ�¹��ɷ�����˾ | 2004-12-01 | — | — | CN | claimed |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | PEYMAN ANUSCHIRWAN (DE) | 2002-05-30 | — | — | US | claimed |
| US-6313119-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | claimed |
| CN-1293662-A | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | AIWENTIS DRUG DEUTSCHLAND GMBH (DE) | 2001-05-02 | — | — | CN | claimed |
| EP-1049677-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037621-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | claimed |
| CN-119954826-A | Compound, preparation method and application thereof, lithium ion battery electrolyte additive and electrolyte | 华鼎国联动力电池有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-4792628-A | ANTIOXIDANTS, ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | SOST, SELPLG, BST2 | CA2 667/4885SMN1; SMN2 2971/4885CA1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.